The emergence of RAS mutations induced by anti-EGFR therapies has been reported in approximately 50% of patients with RASwt CRC and is responsible for acquired resistance to cetuximab (102, 103) (Table 3). The gene discussed is EGFR; the disease is colorectal carcinoma.